RxSight wins FDA nod for light-adjustable IOL
The FDA has cleared RxSight‘s implantable light adjustable intraocular lens and light delivery device.
The company’s RxSight IOL is designed from a UV light reactive material meant to be treated by a specific Light Delivery Device, intended for use 17 to 21 days post-procedure.
The lens is designed to be treated by 3-4 light treatments over 1 to 2 weeks in 40 to 150 second treatment periods, during which the patient must wear UV-protective glasses.
“Until now, refractive errors that are common following cataract surgery could only be corrected with glasses, contact lenses or refractive surgery. This syste...
Source: Mass Device - November 22, 2017 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance rxsight Source Type: news
FDA approves first implanted lens that can be adjusted after cataract surgery to improve vision without eyeglasses in some patients
FDA approved the RxSight Inc. Light Adjustable Lens and Light Delivery Device, the first medical device system that can make small adjustments to the artificial lens ’ power after cataract surgery so that the patient will have better vision when not using glasses. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 22, 2017 Category: American Health Source Type: news
Cambridge Consultants prototypes miniaturized robot for cataract surgery
Cambridge Consultants showed off its prototype of a miniaturized robot designed for cataract surgery last week at its annual Innovation Day event.
The system, Axsis, is one of the smallest known robots for surgical use, according to the firm, featuring instruments of just 1.8mm in diameter.
Get the full story at our sister site, The Robot Report.
The post Cambridge Consultants prototypes miniaturized robot for cataract surgery appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 20, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Optical/Ophthalmic Robotics Surgical Cambridge Consultants Source Type: news
iVeena finishes pilot trial of sustained-release implant
iVeena Delivery Systems said earlier this month that it finished a pilot trial for its IVMED-10 bioerodible implant designed to treat pain and inflammation after cataract surgery.
Placed during cataract surgery, the sustained-release implant delivers dexamethasone for two weeks from the lens capsule.
Get the full story at our sister site, Drug Delivery Business News.
The post iVeena finishes pilot trial of sustained-release implant appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 17, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pain Management Pharmaceuticals Surgical iveenadeliverysystems Source Type: news
Cataract surgery tied to lower risk of early death for older women
(Reuters Health) - Older women with cataracts who get surgery to treat the eye problem may be less likely to die prematurely than those who don ’t get the operations, a recent U.S. study suggests. (Source: Reuters: Health)
Source: Reuters: Health - November 16, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
